Patients in England first to benefit from Sotorasib after drug proven to halt growth of tumours for seven months
Lung cancer patients in England will become the first in Europe to benefit from a “revolutionary” new drug that can halt the growth of tumours by targeting the so-called “Death Star” mutation.
The medication, Sotorasib, will be fast-tracked to NHS patients after it was proven in clinical trials to stop lung cancer growing for seven months.
